AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Histone Lysine N Methyltransferase EZH2, Pipeline Review, H2 2019 - Domainex Ltd, Kainos Medicine Inc, Epizyme Inc & Pfizer Inc - ResearchAndMarkets.com

January 16, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 16, 2020--

The “Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

According to the recently published report ‘Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019’; Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) pipeline Target constitutes close to 19 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes.

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme encoded by EZH2 gene. EZH2 methylates non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. It regulates the circadian clock via histone methylation at the promoter of the circadian genes. It is essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer, involved in the di and trimethylation of Lys-27 of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription.

The report ‘Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019’ outlays comprehensive information on the Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Scope

Reasons to buy

Key Topics Covered

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/e2wpj2

View source version on businesswire.com:https://www.businesswire.com/news/home/20200116005450/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL GENETICS HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/16/2020 08:15 AM/DISC: 01/16/2020 08:16 AM

http://www.businesswire.com/news/home/20200116005450/en